Cargando…

Loxapine in patient with clozapine-resistant psychosis

Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozap...

Descripción completa

Detalles Bibliográficos
Autores principales: Erley, Jennifer, Goldsborough, Sarah, VandenBerg, Amy, Audu, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287867/
https://www.ncbi.nlm.nih.gov/pubmed/34316424
http://dx.doi.org/10.9740/mhc.2021.07.263
_version_ 1783723992191860736
author Erley, Jennifer
Goldsborough, Sarah
VandenBerg, Amy
Audu, Alexandra
author_facet Erley, Jennifer
Goldsborough, Sarah
VandenBerg, Amy
Audu, Alexandra
author_sort Erley, Jennifer
collection PubMed
description Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine.
format Online
Article
Text
id pubmed-8287867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-82878672021-07-26 Loxapine in patient with clozapine-resistant psychosis Erley, Jennifer Goldsborough, Sarah VandenBerg, Amy Audu, Alexandra Ment Health Clin Case Reports Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine. College of Psychiatric & Neurologic Pharmacists 2021-07-16 /pmc/articles/PMC8287867/ /pubmed/34316424 http://dx.doi.org/10.9740/mhc.2021.07.263 Text en © 2021 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Erley, Jennifer
Goldsborough, Sarah
VandenBerg, Amy
Audu, Alexandra
Loxapine in patient with clozapine-resistant psychosis
title Loxapine in patient with clozapine-resistant psychosis
title_full Loxapine in patient with clozapine-resistant psychosis
title_fullStr Loxapine in patient with clozapine-resistant psychosis
title_full_unstemmed Loxapine in patient with clozapine-resistant psychosis
title_short Loxapine in patient with clozapine-resistant psychosis
title_sort loxapine in patient with clozapine-resistant psychosis
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287867/
https://www.ncbi.nlm.nih.gov/pubmed/34316424
http://dx.doi.org/10.9740/mhc.2021.07.263
work_keys_str_mv AT erleyjennifer loxapineinpatientwithclozapineresistantpsychosis
AT goldsboroughsarah loxapineinpatientwithclozapineresistantpsychosis
AT vandenbergamy loxapineinpatientwithclozapineresistantpsychosis
AT audualexandra loxapineinpatientwithclozapineresistantpsychosis